Bongarzone I, Monzini N, Borrello M G, Carcano C, Ferraresi G, Arighi E, Mondellini P, Della Porta G, Pierotti M A
Division of Experimental Oncology A, Istituto Nazionale Tumori, Milan, Italy.
Mol Cell Biol. 1993 Jan;13(1):358-66. doi: 10.1128/mcb.13.1.358-366.1993.
The ret oncogene frequently has been found activated in papillary thyroid carcinomas. A previous characterization of ret activation revealed recombination of its tyrosine kinase domain and sequences derived from an uncharacterized locus (D10S170). The mechanism leading to this recombination was identified as a paracentric inversion of the long arm of chromosome 10, inv(10)(q11.2q21), with the breakpoints occurring where ret and D10S170 were mapped. To further characterize the activation of ret in papillary thyroid carcinomas, we have now isolated and sequenced a second type of ret oncogenic rearrangement not involving the D10S170 locus. The nucleotide sequence indicated that the transforming activity was created by the fusion of the ret tyrosine kinase domain with part of the RI alpha regulatory subunit of protein kinase A (PKA). This is the first example of an oncogenic activity involving a PKA gene. PKA is the main intracellular cyclic AMP receptor, and its RI alpha subunit gene is located on chromosome 17q. RI alpha-ret transcripts encode two isoforms of the chimeric protein (p76 and p81), which display constitutive tyrosine phosphorylation as well as a tyrosine kinase enzymatic activity. Under nonreducing conditions, both isoforms are found in a dimeric configuration because of both homo- and heterodimer formation. Thus, the in vivo activation of ret in human papillary thyroid carcinomas is provided by the fusion of its tyrosine kinase domain with different genes and can be mediated by different mechanisms of gene rearrangement.
RET原癌基因在甲状腺乳头状癌中经常被发现处于激活状态。先前对RET激活的特征描述显示,其酪氨酸激酶结构域与来自一个未鉴定基因座(D10S170)的序列发生了重组。导致这种重组的机制被确定为10号染色体长臂的臂间倒位,inv(10)(q11.2q21),断点发生在RET和D10S170被定位的位置。为了进一步表征RET在甲状腺乳头状癌中的激活情况,我们现在分离并测序了第二种不涉及D10S170基因座的RET致癌重排类型。核苷酸序列表明,转化活性是由RET酪氨酸激酶结构域与蛋白激酶A(PKA)的RIα调节亚基的一部分融合产生的。这是涉及PKA基因的致癌活性的首个例子。PKA是主要的细胞内环磷酸腺苷受体,其RIα亚基基因位于17号染色体q臂上。RIα-RET转录本编码嵌合蛋白的两种异构体(p76和p81),它们表现出组成型酪氨酸磷酸化以及酪氨酸激酶酶活性。在非还原条件下,由于同型和异型二聚体的形成,两种异构体都以二聚体形式存在。因此,人甲状腺乳头状癌中RET的体内激活是由其酪氨酸激酶结构域与不同基因的融合提供的,并且可以由不同的基因重排机制介导。